- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02764047
Probiotics in the Treatment of NAFLD
Effect of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Design The study is a single-center double blind, placebo controlled, parallel group study. Patients were randomized to receive either the probiotic supplement (1.109 Lactobacillus acidophilus ATCC SD5221 and 1.109 Bifidobacterium lactis HN019) or placebo for 6 months. All participants receive individualized dietary couseling sessions with a nutritionist.
Randomization Randomization was performed using the website www.randomization.com. The allocation sequence remained concealed throughout the study. Researchers, outcome assessors and patients were blinded to the treatment received.
The trial was registered at www.clinicaltrials.gov. (number NCT02764047)
Intervention Patients receive the probiotic or placebo supplement in identical medicine bottles to maintain blinding. The instruction for administration of the capsules is taking 1 capsule per day before bedtime with 1 cup of water. Patients are also advised to keep medications in use without change until the end of the study and to communicate the investigators if they used antibiotics.
Questionary - Profile and the risk factors for fibrosis and NASH The profile of patients with NASH will be analyzed according to the variables collected (age, gender, smoking, diabetes, hypertension, high blood pressure, heart rate, weight, height, BMI, waist circumference, AST, ALT, total bilirubin, albumin, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, insulin, C-reactive protein, platelets), as well as the possible risk factors for the development of the disease. It is believed that the interaction between diet, intestinal microbiota and genetic background is the most important in the development and progression of NAFLD.
Participants are requested to bring all medication they use or a list from their pharmacists to the research center. During a medication interview generic name, dose and frequency are registered by trained staff.
Nutritional and Physical assessment Height is measured at baseline to confirm BMI. At 0 (baseline), 3 and 6 months body weight is measured using a calibrated balance, waist circumference, systolic blood pressure, diastolic blood pressure, heart rate. Body composition is assessed at baseline and 6 months phase angle of bioelectrical impedance analysis (BIA) method, hand grip strength.
Biopsy, Fibromax and NAFLD score Improvement in liver injury will be defined by reduction of fibrosis, steatosis and inflammation in liver biopsy and noninvasive tests Fibromax test and NAFLD score of varying degrees. NAFLD score and the FibroMax ™ test (Biopredictive, Paris, France), which evaluates fibrosis, inflammation and hepatic steatosis. Sensitivity, specificity, positive and negative predictive values will be assessed for comparison of these non-invasive fibrosis assessment methods with liver biopsy. Hepatic transaminases (AST, ALT) will be assessed as well.
Biochemical markers - General labs and Cytokines sample At baseline, 3 and 6 months, a fasting blood sample is taken for measurement of plasma laboratory tests (AST, ALT, total bilirubin, albumin, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, insulin, C-reactive protein, platelet), serum -1 leptin and MCP will be quantified. To determine levels of serum leptin and MCP-1, 15 mL venous blood samples were taken from the antecubital vein, and transferred to tubes without anticoagulant (4 mL). Blood samples were collected between 9:00 a.m. and 11:00 a.m., at baseline (PRE), after 3 months and after 6 months. Tubes without anticoagulant were centrifuged at 1048g for 10 min. Serum samples were then divided into several aliquots and stored at -20 °C for further analysis. Serum leptin and MCP-1 levels were determined using the enzyme-linked immunosorbent assay (ELISA) method, using the specific kit (Peprotech, EUA) following the manufacturer's instructions. All samples were measured in duplicate by microplate reader SpectraMax M2e (Molecular Devices, EUA). Intra-assay coefficients of variation were always <5.0%, 3.8% for BDNF and cortisol, respectively.
Gut microbiota - Stool sample Fecal samples are collected by patients in their own bottle and delivered to the Nutrition Clinic in Hepatology Hospital Santa Clara Santa Casa Hospital Complex. The samples are transported to the Immunology Laboratory. Samples are aliquoted in 4 samples, frozen, and stored in -20 and -80 degrees freezers. At the end of the collections, DNA will be extracted (MoBio PowerFecal® DNA Isolation Kit). DNA samples will be sent to the University Institute Research Center of Cardiology and Pneumology at the University of Quebec Laval. Genetic sequencing of the microflora in the samples will be performed. Results will be analyzed and correlated with clinical outcomes.
Food record Eligible patients will be submitted to food assessment using a food frequency questionnaire validated for liver diseases, and a 24-hour recall survey used for possible comparisons with the food frequency questionnaire. The multiple-step method for performing is applied during the patient interview, aiming to improve collection accuracy and reduce memory bias.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
RS
-
Porto Alegre, RS, Brazil, 900200090
- Recruiting
- Irmandade Santa Casa de Misericórdia
-
Contact:
- Cristiane V Tovo, PHD
- Phone Number: 555191893113
- Email: cris.tovo@terra.com.br
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years, patients with NASH confirmed by biopsy within 6 months before inclusion.
Exclusion Criteria:
- Patients with hepatitis B virus, hepatitis C virus, alcohol consumption significantly (> 14 drinks per week for women and> 21 drinks per week for men) (Chalasani, 2012), history of decompensated liver disease (ascites, esophageal varices, encephalopathy), hepatocellular carcinoma, steroids, methotrexate, amiodarone, tamoxifen, valproate, vitamin E past 6 months, previous surgery (bariatric, gastric, intestinal resection), parenteral nutrition (TPN) the last 6 months, pregnancy or breastfeeding, history of hypothyroidism, Cushing's syndrome, diabetes type 1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo capsule
|
L. acidophilus 10⁹, B. lactis 10⁹
|
Active Comparator: Probiotic
Probiotic capsule
|
L. acidophilus 10⁹, B. lactis 10⁹
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hepatic changes (histological)
Time Frame: 6 months
|
The assessment of fibrosis will be performed in all patients using noninvasive FIBROMAX test (evaluates fibrosis, inflammation and hepatic steatosis) for comparison with liver biopsy.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hepatic changes (enzymatic)
Time Frame: 6 months
|
The assessment of enzymatic activity will be performed in all patients via measurements of AST , ALT .
|
6 months
|
Lipid profile
Time Frame: 6 months
|
The assessment of lipid profile will be performed in all patients via measurements of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
|
6 months
|
Alterations in gut microbiota
Time Frame: 6 months
|
The evaluation of the intestinal microbiota will be performed in all patients by molecular analysis of stool dna test .
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Cristiane V Tovo, PHD, FUHSPA
Publications and helpful links
General Publications
- Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013 Oct 28;19(40):6911-8. doi: 10.3748/wjg.v19.i40.6911.
- Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005 Jul;39(6):540-3. doi: 10.1097/01.mcg.0000165671.25272.0f.
- Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013 Mar-Apr;12(2):256-62.
- Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial. Int J Prev Med. 2013 May;4(5):531-7.
- Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011 Sep;15(9):1090-5.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 852.771
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-alcoholic Fatty Liver Disease
-
Naga P. ChalasaniDSM Nutritional Products, Inc.CompletedNon-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Non-Alcoholic Fatty LiverUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
Better TherapeuticsArizona Liver HealthCompletedNon-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty LiverUnited States
-
Puerta de Hierro University HospitalHospital Universitario Marqués de ValdecillaNot yet recruitingNon-Alcoholic Fatty Liver Disease | Non Alcoholic SteatohepatitisSpain
-
BASF ASUnknownNASH - Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver Disease | Non Alcoholic Fatty LiverUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
Clinical Trials on Probiotic
-
King's College Hospital NHS TrustCompleted
-
Fudan UniversityInner Mongolia Yili Industrial Group Co., LtdCompletedObesity | AdiposityChina
-
Maastricht University Medical CenterCompleted
-
Centros de Investigación de Nutrición y SaludNutribioticaCompletedFunctional ConstipationSpain
-
Universiti Kebangsaan Malaysia Medical CentreUnknownHypertension | Obesity | Type 2 Diabetes Mellitus | HyperlipidemiaMalaysia
-
BiocodexCompletedAcute GastroenteritisArgentina
-
Fundació Sant Joan de DéuCompleted
-
University of LeedsUnknown
-
Centro Pediatrico Albina de PatinoCompletedAcute Gastroenteritis | Acute DiarrheaBolivia
-
Shandong UniversityUnknownGastrointestinal Neoplasms | Colorectal Cancer | Malnutrition | Effects of Chemotherapy | Tumor ImmunityChina